natgillin/translations-raw huggingface dataset:
A lead-free solder alloy for joining a Cu electrode which contains an Ni plating layer, the solder alloy having an alloy composition which consists of 31 to 59 mass % of Bi, 0.3 to 1.0 mass % of Cu, 0.01 to 0.06 mass % of Ni, and at least one element selected from the group consisting of 0.001 to 0.07 mass % P and 0.001 to 0.03 mass % Ge, and a balance of Sn wherein the solder alloy has a melting point of 185 degrees C or less, a tensile strength of 70 MPa or more and elongation of 65 % or more. 
PATENTNI ZAHTJEVI Legura za lemljenje bez olova za spajanje Cu elektrode koja sadrži sloj premaza od Ni, legura za lemljenje ima sastav legure koji se sastoji od 31 do 59 masenih % Bi, 0.3 do 1.0 masenih % Cu, 0.01 do 0.06 masenih % Ni, te barem jedan element koji je odabran iz skupine koja sadrži 0.001 do 0.07 masenih % P 1 0.001 do 0.03 masenih % Ge, i ravnotežni udio Sn pri čemu legura za lemljenje ima talište od 185 stupnjeva C ili manje, vlačnu čvrstoću od 70 MPa ili više 1 istezanje od 65 % ili više.
Thus compounds of formula (III) may be prepared from the compound of formula (IV) wherein R1, R2 and R3 have the meanings defined in formula (1), R7 is 2-benzyloxyphenyl and R8 is N-benzyloxycarbonyl by the reaction with hydrogen in the presence of a palladium on charcoal catalyst and acetic acid. 
HR NR 6, CHO R (IV) gdje Ri, R2 i R3 znače kao što je definirano za formulu (1), R; je 2-benziloksifenil, a Ra je N-benziloksikarbonil, reakcijom s vodikom, u prisutnosti paladija na drvenom ugljenu kao katalizatora i octene kiseline.
Selective extraction of the compound of interest. 
Broj objave europskog patenta:
After 18.5 hours, additional TEA (1.5mL) and Ac2O (1mL) were added. 
Nakon 18.5 sati je bila dodana dodatna količina TEA (1.5 mL) i Ac20 (1 mL).
In particular the rate of application of Imazamox is usually 0.1 to 200 g/ha, as a rule, 1 to 100 g/ha, preferably 2 to 100 g/ha, of active substance (a.s.). 
Stopa primjene imazamoksa je obično 0.1 do 200 g/ha, kao pravilo, 1 do 100 g/ha, poželjno 2 do 100 g/ha aktivne supstance.
The anti-CLDN6 antibody of claim 1, which exhibits one or more immune effector functions against a cell carrying CLDN6 in its native conformation, wherein the one or more immune effector functions are preferably selected from the group consisting of complement dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), induction of apoptosis, and inhibition of proliferation, preferably the effector functions are ADCC and/or CDC. 
Antitijelo suglasno bilo kojem od zahtjeva 1-7, koje pokazuje jednu ili više imunskih efektorskih funkcija usmjerenih prema stanicama koje pokazuju CLDNE6 u njegovoj nativnoj formi, naznačeno time da je jedna ili više efektorskih funkcija poželjno izabrana iz grupe koji čine citotoksičnost zavisna od komplementa (CDC), citotoksičnost posredovana antitijelima (ADCC), indukcija apoptoze i mhibicija proliferacije, a poželjno je da su efektorske funkcije ADCC i/ili CDC.
The apparatus according to claim 2, further comprising an ice breaker to break off an ice cube from the first ice column while the mould is in place around the second elongated element. The apparatus according to claim 8, wherein the mould parts are movable at least by means of a rotational movement of the first rigid element and/or the second rigid element around an axis of rotation, and the first elongated element and the second elongated element are arranged around and parallel to the axis of rotation. 
– razmicanja dijelova kalupa koji tvore kalup oko prvog izduljenog elementa kada se dobije prvi stupac leda u kalupu, i – tvorbe kalupa oko drugog izduljenog elementa među izduljenim elementima; i uklanjanja prvog stupca leda s prvog izduljenog elementa dok je kalup smješten oko drugog izduljenog elementa.
A compound of this invention will generally be used as an invertebrate pest control active ingredient in a composition, i.e. formulation, with at least one additional component selected from the group consisting of surfactants, solid diluents and liquid diluents, which serves as a carrier. 
Spoj prema patentnom zahtjevu 1 koji je izabran iz grupe koju čine: HR P20140196 T1 Kompozicija koja sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 8 i najmanje jednu dodatnu komponentu izabranu iz grupe koju čine surfaktanti, kruti razblaživači i tekući razblaživači.
or a salt thereof, said process comprising: the reaction of the compound of formula I-1 wherein G1 represents halogen, or a salt of said compound, with 2-(tert-butoxy)ethanol in the presence of a base at a temperature from 25 to 140° C. to obtain the compound of formula I-2 as defined in claim 1, or a salt of said compound, and 
I-1 gdje G' predstavlja halogen, ili soli navedenog spoja, s 2-(tert-butoksijetanolom u prisutnosti lužine na temperaturi od 25 do 140*C, kako bi se dobio spoj formule I-2 kao što je definirano u zahtjevu 1, ili sol navedenog spoja, i reakcija spoja ili soli dobivenog/dobivene u koraku a) s TiCly u aprotonskom otapalu ili u smjesi otapala.
In a further aspect, the present invention concerns a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) as specified herein, or a compound of any of the subgroups of compounds of formula (I) as specified herein, and a pharmaceutically acceptable carrier. 
21. Postupak za dobivanje farmaceutskog pripravka prema zahtjevu 20, naznačen time da se navedeni postupak sastoji 10 od bliskog miješanja farmaceutski prihvatljivog nosača sa terapeutski učinkovitom količinom spoja kako je zatraženo u bilo kojem od zahtjeva 1 do 18 22.
C3-6cycloalkyl substituted with one or two groups selected from: -C(O)OR9, -C(O)NR9R10, 
C3-6cikloalkil supstituiran s jednom ili dvije skupine odabrane od sljedećih:
the shredding-system (40) is assigned to the electric arc furnace (10) for shredding discarded iron and/or steel junk (scrap 70), 
drobilica (40) je - - priključena na elektrolučnu peć (10) za drobljenje odbačenog željeza i/ili čeličnog otpada (odlomak -
In the following, the invention is illustrated by means of some examples. Embodiment 
U dijelu koji slijedi, ovaj izum je prikazan uz pomoć nekih primjera.
Aerosol generating means 12 includes a plurality of glass beads 20 coated with an aerosol forming substance or substances, such as glycerin. 
Sredstvo 12 za generiranje aerosola uključuje mnoštvo staklenih perli 20 koje su prevučene sa jednom ili više supstanci za formiranje aerosola, kao što je glicerin.
A pharmaceutically acceptable salt of a compound of claim 1 or a composition thereof for use in the treatment of a disorder selected from the group consisting of autoimmune disorders, inflammatory disorders, and cancers. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1-10, ili njegov pripravak, naznačen time što je namijenjen upotrebi u liječenju poremećaja kojeg se bira iz skupine koju čine autoimuni poremećaji, upalni poremećaji, te razni oblici raka.
A packaging according to any of the preceding claims, wherein the first and/or second side and/or hinging part comprises one or more protrusions adapted to push the stored element towards the first or second side of the inner part, when the packaging is closed. 
Pakiranje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time, što prva i/ili druga strana i/ili zglobni dio sadržavaju jedno ili više izbočenja koja su prilagođena tako da pogurnu pohranjeni element prema prvoj ili drugoj strani unutarnjeg dijela, kada je pakiranje zatvoreno.
A composition according to claim 8, which comprises a safener in addition to the compound of formula I. 
Sastav prema zahtjevu 21, naznačen time, da sadrži zaštitno sredstvo kao dodatak uz spoj formule I.
An isolated or recombinant polypeptide comprising a polypeptide sequence having at least 95% sequence identity to SEQ ID NO:50, wherein the polypeptide binds human CD80 or human CD86 or an extracellular domain of either and has an ability to inhibit an immune response that is greater than the ability of a LEA29Y polypeptide comprising the polypeptide sequence shown in SEQ ID NO:168 to inhibit an immune response. 
Izolirani ili rekombinantni polipeptid koji sadrži polipeptidnu sekvencu koja se razlikuje od SEQ ID NO:36 u ne više od 6 aminokiselinskih ostataka i koja uključuje ostatke na položajima 24, 30, 32, 41, 50, 54, 55, 56, 64, 65, 70, 85, 104 i 106 koji su identični sa aminokiselinskim ostatcima na odgovarajućim položajima u SEQ ID NO:36, naznačen time da polipeptid veže humani CD80 ili humani CD86 ili izvanstaničnu domenu bilo kojeg od njih i ima sposobnost inhibicije imunološkog odgovora koja je veća od sposobnosti inhibicije imunološkog odgovora polipeptida LEA29Y koji sadrži polipeptidnu sekvencu koja je prikazana u SEQ ID NO:168.
In particular, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I, alone or in combination with a pharmaceutically acceptable carrier. 
Posebno, ovaj izum osigurava farmaceutsku kompoziciju koja sadrži terapeutski efikasnu količinu spoja formule I, samog ili u kombinaciji sa farmaceutski prihvatljivim nosačem.
In a preferred embodiment, any such mutein has at least 40% identity or homology with the sequence of either an IL-18BP or a virally-encoded IL-18BP homologue, as defined in WO 99/09063. 
U poželjnom obliku, bilo koji takav mutein ima najmanje 40% istovjetnosti ili homologije sa slijedom bilo IL-18BP, bilo virusom kodiranog homologa IL-18BP, kako je definirano u WO 99/09063.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) fenpropimorph. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) spoj koji je izabran između slijedećeg: difenokonazola, propikonazola, kiprokonazola i epoksikonazola.
Further, lubricants can also be present as excipients, such as stearic acid, magnesium stearate, calcium stearate, sodium laurylsulphate, hydrogenated vegetable oil, hydrogenated castor oil, sodium stearyl fumarate, talc, or macrogols or mixtures thereof. 
Nadalje, u pripravku kao ekscipijensi također mogu biti prisutna i maziva, kao što su primjerice stearinska kiselina, magnezijev stearat, natrijev laurilsulfat, hidrogenizirano biljno ulje, hidrogenizirano ricinusovo ulje, natrijev stearil fumarat, talk, ili makrogol ili smjese istog.
The process for the stereoselective preparation according to claim 7, wherein the compound of formula (VII) is subjected to a Sharpless asymmetric dihydroxylation reaction using a suitable chiral ligand to obtain the compound of formula (VI), or alternatively the compound of formula (VI′), 
9. Postupak stereoselektivne pripreme prema zahtjevu 8, gdje se spoj formule (VII) (Vi) podvrgava reakciji Sharpless-ove asimetrične dihidroksilacije pomoću odgovarajućeg kiralnog liganda radi dobivanja spoja formule (VI), ili alternativno spoja formule (VT),
45; and an antibody comprising: a light chain comprising, according to Kabat, the CDR-L1 of the sequence SEQ ID No. 
41, te – teški lanac lanac koji prema Kabat sadrži CDR-H1 sekvencije SEQ ID No.
Modified Saccharides of the Invention The invention provides a modified capsular saccharide comprising a blocking group at a hydroxyl group position on at least one of the monosaccharide units of the corresponding native capsular saccharide. 
Modificirani saharid iz kapsule, koji sadrži blokirajuću skupinu na položaju hidroksilne skupine u najmanje 80% monosaharidnih jedinica odgovarajućeg nativnog saharida kapsule, gdje blokirajuća skupina ima formulu (Ia):
Liquid preparations for oral administration may also be prepared in the form of a dry powder to be reconstituted with a suitable solvent prior to use. 
Tekući preparati za oralnu uporabu mogu također biti priređeni u obliku suhih prahova koji se trebaju otopiti s pogodnim otapalom neposredno prije uporabe.
providing a drawing roller for applying tension to the film web on an unprinted side after printing and before flame drying, so that web tension in the flame drying area is reduced compared with web tension in a printing area, wherein the drawing roller is a driven vacuum roller provided with a plurality of openings formed on its lateral surface and is set up to apply negative pressure to the film web through the openings. 
Postupak tiskanja i sušenja umjetne folije (2), osobito PP, PS ili PE folije, gdje se foliju (2) tiska ofsetnim tiskom različitim načinima otiskivanja tinte, a zatim podvrgava sušenju plamenom na otisnutoj strani, naznačen time što se foliju nakon tiskanja i prije sušenja plamenom podvrgava vlačnoj napetosti na neotisnutoj strani, tako da napetost folije u području sušenja plamenom bude smanjena u usporedbi s napetošću folije u području tiskanja.
The sewing or looping head according to claim 1, wherein said cutting element is scissor-shaped and works on a cutting plane that is substantially perpendicular to the direction of orientation of the tip of said supporting hook of the sewing chain stitch. 
Glava za šivanje ili pravljenje petlji u skladu s patentnim zahtjevom 3, naznačena time, da je navedena ravnina rezanja (31) okrenuta prema glavi (6a) navedene kuke (6), koja podupire lančani šav (30).
A process of providing a molten material comprising introducing solid batch material into a melter, and melting the solid batch material in the melter by submerged combustion to afford a melt, and subjecting the melt to a flow pattern which when simulated by means of Computational Fluid Dynamics analysis shows a substantially toroidal melt flow pattern generated in the melt in the melter, comprising major centrally inwardly convergent flow vectors at the melt surface followed by downward oriented flow in proximity of the central axis of revolution of the toroidal melt flow pattern, with the central axis of revolution of the toroidal melt flow pattern being substantially vertical. 
HR P20190591 T1 PATENTNI ZAHTJEVI Postupak dobivanja rastaljenog materijala koji se sastoji u unosu šarže čvrstog materijala u talionik i taljenju šarže čvrstog materijala u talioniku uronjenim izgaranjem, naznačen time što se sastoji u podvrgavanju taline u uzorak tečenja koji pokazuje toroidni uzorak tečenja taline stvoren u talini u talioniku, koji sadrži glavne središnje prema unutra usmjerene konvergentne vektore tečenja na površini taline, gdje je središnja os vrtnje toroida okomica, gdje se uzorak tečenja taline određuje simuliranjem računalnom analizom dinamike fluida.
or a heterocycle selected from the group consisting of: pyrrolidine, indoline and tetrahydroisoquinoline. 
- ili heterociklilčka skupina odabrana iz sljedeće skupine: pirolidin, indolin te tetrahidroizokinolim.
Data transmission device 1 also comprises a watchdog circuit 18, which receives an enabling signal from each microprocessor 6a, 6b via the interposition of a third optoisolator 19 to keep microprocessors 6a, 6b galvanically isolated. 
Naprava za prijenos podataka 1 također sadržava kontrolni (watchdog) električki krug 18, koji prima omogućujući signal iz svakog mikroprocesora 6a, 6b putem umetanja trećeg optoizolatora 19 da drži mikropocesore 6a, 6b galvanski izoliranim.
When haziness and crystal formation is evident, the agitation speed is slowed and stirring continued for 12 h at room temperature. 
Kada je zamućenje i nastajanje kristala očigledno, brzinu miješanja se smanji, a s miješanjem nastavi još 12 sati na sobnoj temperaturi.
isolating mature type I elastase; and lyophilizing said isolated mature type I elastase, 
(b) opcionalno, pročišćavanje zrelog tipa I elastaze; 1
R1b represents H; 
R'" predstavlja H;
The method of claim 21, wherein the host cell is a mammalian cell, preferably a CHO cell. 
Postupak prema patentnom zahtjevu 20, naznačen time što je stanica domaćin stanica sisavca, ili stanica Escherichia coli, poželjno gdje je stanica sisavca CHO stanica.
The coating composition according to any one of the preceding claims, wherein the polysiloxane-based binder system constitutes at least 40 % by dry weight of the coating composition, wherein the hydrophilic-modified polysiloxanes constitute 0.05-10 % by dry weight of the coating composition, said hydrophilic-modified polysiloxane being a poly(oxyalkylene)-modified polysiloxane, and wherein the one or more biocides constitutes 0.1-10 % by dry weight of the coating composition, said coating composition having a viscosity in the range of 200-4,000 mPa·s measured at 25 °C in accordance with ISO 2555:1989, and said coating composition further comprises pigments and/or fillers in an amount of 0-35 % by dry weight of the coating composition. 
Smjesa za premaz prema jednom od prethodno navedenih patentnih zahtjeva, naznačena time da sustav veziva na bazi polisiloksana čini najmanje 40% suhe mase smjese za premaz, pri čemu hidrofilno modificirani polisiloksani čine 0,05-10% suhe mase smjese za premaz pri čemu je navedeni hidrofilno modificirani polisiloksan poli(oksialkilen)-modificirani polisiloksan 1 pri čemu jedan ili više biocida čine 0.1-10% suhe mase smjese za premaz, pri čemu navedena smjesa za premaz ima viskoznost u rasponu od 200-4.000 mPa:s mjereno na 25 *C u skladu s normom ISO 2555:1989, te pri čemu navedena smjesa za premaz sadrži i pigmente i/ili punila u količini od 0-35% suhe mase smjese za premaz.
The reduced level of melanoidins and other colour contributing substances is also evident by a low colour intensity, particularly at wavelengths around 600 nm. 
Snižena razina melanoidina i drugih tvari koje doprinose obojenju se također očituje niskim intenzitetom boje, naročito pri valnim duljinama oko 600 nm.
The compound according to claim 1, wherein Cy2 represents a phenyl group, a pyridinyl group, a pyrazolyl group, a morpholinyl group, a furanyl group or a cyclopropyl group. 
Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time, da Cy2 predstavlja fenilnu skupinu, skupinu piridinila, skupinu pirazolila, skupinu morfolinila, skupinu furanila ili ciklopropilnu skupinu.
The organic layer was collected and the aqueous phase washed with additional chloroform (2 x 150 ml). 
Organski sloj se sakupi i vodena faza se ispere dodatnim kloroformom (2 x 150 ml).
Use according to claim 1, wherein said autoimmune disease is Multiple Sclerosis (MS), Crohn's disease, rheumatoid arthritis, type 1 diabetes mellitus, psoriasis, lupus, ulcerous colitis, vitiligo, coeliac disease, vasculitis, dermatomyositis, polymyositis, thyroiditis (Hashimoto, Graves), myasthenia gravis, Guillain-Barre syndrome, uveitis, flat lichen, temporal arteritis, sarcoidosis, dry syndrome (Sjöegren), bronchial asthma, pemphigus, ankylosing spondilitis, sclerodermia, fibromyalgia or rheumatic fever. 
Uporaba prema zahtjevu 1, gdje je navedena autoimuna bolest multipla skleroza (MS), Chronova bolest, reumatoidni artritis, dijabetes melitus tipa 1, psorijaza, lupus, ulcerozni kolitis, vitiligo, celijakija, vaskulitis, dermatomiozitis, polimiozitis, tirozitis (Hashimoto, Graves), mijastenija gravis, Guillain-Barrov sindrom, uveitis, lihen planus, temporalni artritis, sarkoidoza, suhi sindrom (Sjčegren), bronhijalna astma, plikovnjača, ankilozantni spondilitis, sklerodermija, fibromialgija ili reumatska groznica.
Thus in one embodiment the present invention relates to a method for diagnosing islet amyloidosis indicative of presymptomatic or clinical diabetes mellitus type 2 (T2D) and/or of beta-cell failure following clinical pancreatic islet transplantation in a subject, comprising a step of determining the presence of an antibody that binds to a peptide as defined above in a biological sample of said subject. 
Postupak za dijagnosticiranje amiloidoze otočića koji ukazuje na presimptomatski ili klinički dijabetes melitus tipa 21/1ili zatajenje beta-stanica nakon kliničke transplantacije otočića pankreasa kod subjekta, naznačen time, da obuhvaća korak određivanja prisutnosti protutijela koje se veže na peptid u skladu s patentnim zahtjevom 17, u biološkom uzorku navedenog subjekta.
The composition of claim 1 or 2 characterized in said monocarboxylic acid is a concentrated acid of more than 84% by weight, preferably more than 90%, more preferably 99% or more. 
Pripravak prema zahtjevu 4 ili 5, naznačen time što je ta monokarboksilna kiselina koncentrirana kiselina više od 90%, poželjnije 99% ili više.
The process of any of claims 1 to 2, wherein the percent amount of the water soluble species by weight in the extraction solution is a value in a range selected from the group consisting of 0.25% to 13%, 0.5% to 8%, 0.8% to 5%, and 1.25% to 4%. 
Proces iz bilo kojeg od patentnih zahtjeva 1 do 2, gdje postotna količina u vodi topljivih vrsta po masi u ekstrakcijskoj otopini je vrijednost u opsegu odabranom iz grupe koja se sastoji od 0.25% do 13%, 0.5% do 8%, 0.8% do 5%, 1 1.25% do 4%.
Consequently, great care must be exercised when handling lactonizable compounds to isolate them in high yield. 
Posljedično, potreban je veliki oprez pri obradi spojeva koji mogu prijeći u oblik laktona, kako bi se izolirali u visokom prinosu.
The compound for use according to claim 1, wherein the method further comprises administering a therapeutically effective amount of a second active agent or a support care therapy. 
Spoj za uporabu u skladu s patentnim zahtjevom 1, pri čemu metoda sadrži primjenu terapeutski učinkovite količine druge aktivne tvari ili suportivne terapije.
Use according to claim 11 for prophylaxis and therapy of inflammatory diseases of the skin and in particular psoriasis. 
Spoj prema zahtjevu 9 naznačen time da je za profilaksu i liječenje upalnih bolesti kože i naročito psorijaze.
The antibody, immunoconjugate, pharmaceutical composition, bispecific or multispecific molecule or expression vector for use according to claim 25, wherein the disease is multiple myeloma. 
Antitijelo, imunokonjugat, bispecifična ili multispecifična molekula, farmaceutski pripravak ili vektor ekspresije za primjenu prema zahtjevu 19, naznačen time, što je bolest ili poremećaj multipli mijelom.
0.02 gram or 0.04 gram of roflumilast is added, and the mixture is stirred until a clear solution is obtained. 
Doda se 0.02 grama ili 0.04 grama roflumilasta i smjesa se miješa do dobivanja bistre otopine.
Identification assembly according to any of the preceding claims, wherein the adjacent surface (14) comprises a laser sensitive material (26) which produces a visible pattern when irradiated by a laser. 
Sklop za identifikaciju prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu se susjedna površina (14) sastoji od materijala osjetljivog na uporabu lasera (26) koji daje vidljivi uzorak kad je ozračen laserom.
Other embodiments include compounds having the formula wherein R5 is hydrogen or p-methoxybenzyl; R4 is selected from the group consisting of hydrogen, 
Tvar u skladu s patentnim zahtjevom 12, gdje je radioizotop odabran iz grupe koja se sastoji od '*F, 1261.